Beacon Harbor Wealth Advisors Inc. Invests $5.81 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Beacon Harbor Wealth Advisors Inc. purchased a new stake in Krystal Biotech, acquiring 32,235 shares valued at approximately $5.81 million, representing 0.11% ownership as of the latest SEC filing.
• Insider Suma Krishnan sold 13,435 shares for about $2 million, reducing their ownership by 0.92% after the transaction.
• Krystal Biotech reported earnings of $1.29 per share for the latest quarter, exceeding analyst expectations and generating revenues of $96.04 million, also above estimates.

Beacon Harbor Wealth Advisors Inc. purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund purchased 32,235 shares of the company's stock, valued at approximately $5,812,000. Beacon Harbor Wealth Advisors Inc. owned about 0.11% of Krystal Biotech as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its holdings in Krystal Biotech by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company's stock valued at $45,168,000 after acquiring an additional 7,344 shares during the last quarter. Evolutionary Tree Capital Management LLC increased its holdings in shares of Krystal Biotech by 24.7% during the 1st quarter. Evolutionary Tree Capital Management LLC now owns 13,343 shares of the company's stock worth $2,406,000 after buying an additional 2,643 shares during the last quarter. Blair William & Co. IL increased its holdings in shares of Krystal Biotech by 26.7% during the 1st quarter. Blair William & Co. IL now owns 9,433 shares of the company's stock worth $1,701,000 after buying an additional 1,990 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Krystal Biotech by 27.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,141 shares of the company's stock worth $386,000 after buying an additional 461 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Krystal Biotech during the 1st quarter worth $757,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 0.0%

NASDAQ:KRYS traded up $0.05 on Monday, reaching $138.71. The stock had a trading volume of 91,880 shares, compared to its average volume of 333,443. The company has a 50-day moving average of $141.94 and a 200 day moving average of $155.38. The stock has a market cap of $4.01 billion, a P/E ratio of 28.19 and a beta of 0.70. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. On average, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 49,800 shares of company stock valued at $7,487,943. Corporate insiders own 13.70% of the company's stock.

Analysts Set New Price Targets

KRYS has been the subject of a number of research analyst reports. Bank of America dropped their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Chardan Capital restated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday, August 5th. Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Friday, July 25th. Finally, Citigroup reiterated a "neutral" rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of "Buy" and an average target price of $210.22.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).